KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Acadia Pharmaceuticals (ACAD) Gross Margin (2016 - 2025)

Acadia Pharmaceuticals has reported Gross Margin over the past 10 years, most recently at 90.77% for Q4 2025.

  • Quarterly results put Gross Margin at 90.77% for Q4 2025, down 84.0% from a year ago — trailing twelve months through Dec 2025 was 91.69% (up 24.0% YoY), and the annual figure for FY2025 was 91.69%, up 24.0%.
  • Gross Margin for Q4 2025 was 90.77% at Acadia Pharmaceuticals, down from 92.23% in the prior quarter.
  • Over the last five years, Gross Margin for ACAD hit a ceiling of 98.59% in Q1 2023 and a floor of 88.85% in Q1 2024.
  • Median Gross Margin over the past 5 years was 92.78% (2023), compared with a mean of 94.42%.
  • Biggest five-year swings in Gross Margin: surged 645bps in 2022 and later crashed -974bps in 2024.
  • Acadia Pharmaceuticals' Gross Margin stood at 91.78% in 2021, then increased by 7bps to 98.23% in 2022, then decreased by -6bps to 92.26% in 2023, then fell by -1bps to 91.6% in 2024, then dropped by -1bps to 90.77% in 2025.
  • The last three reported values for Gross Margin were 90.77% (Q4 2025), 92.23% (Q3 2025), and 92.16% (Q2 2025) per Business Quant data.